1519 related articles for article (PubMed ID: 26997539)
41. Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH.
Morin J; Swanson TA; Rinaldi A; Boucher M; Ross T; Hirenallur-Shanthappa D
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33970131
[TBL] [Abstract][Full Text] [Related]
42. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
43. Epidemiology of Non-alcoholic Fatty Liver Disease in North America.
Arshad T; Golabi P; Henry L; Younossi ZM
Curr Pharm Des; 2020; 26(10):993-997. PubMed ID: 32124690
[TBL] [Abstract][Full Text] [Related]
44. Transient Elastography in HIV Infected Patients with Liver Steatosis Identifies a High-Risk Group for Non-Alcoholic Steatohepatitis.
Pezzini MF; Cheinquer H; de Araujo A; Schmidt-Cerski CT; Sprinz E; Herz-Wolff F; Poeta J
Curr HIV Res; 2021; 19(4):311-316. PubMed ID: 33632105
[TBL] [Abstract][Full Text] [Related]
45. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
[TBL] [Abstract][Full Text] [Related]
46. Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques.
Karlas T; Berger J; Garnov N; Lindner F; Busse H; Linder N; Schaudinn A; Relke B; Chakaroun R; Tröltzsch M; Wiegand J; Keim V
World J Gastroenterol; 2015 Apr; 21(16):4894-902. PubMed ID: 25945002
[TBL] [Abstract][Full Text] [Related]
47. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.
Rosenblatt R; Mehta A; Snell D; Hissong E; Kierans AS; Kumar S
Dig Dis Sci; 2019 Jan; 64(1):262-268. PubMed ID: 30269271
[TBL] [Abstract][Full Text] [Related]
48. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
Vilar-Gomez E; Chalasani N
J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018.
Kim D; Cholankeril G; Loomba R; Ahmed A
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1499-1501.e2. PubMed ID: 32801011
[TBL] [Abstract][Full Text] [Related]
50. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
[TBL] [Abstract][Full Text] [Related]
51. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
Santiago-Rolón A; Purcell D; Rosado K; Toro DH
P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
[TBL] [Abstract][Full Text] [Related]
52. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
53. Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology.
Corey KE; Misdraji J; Gelrud L; King LY; Zheng H; Malhotra A; Chung RT
Dig Dis Sci; 2015 Aug; 60(8):2523-8. PubMed ID: 25840922
[TBL] [Abstract][Full Text] [Related]
54. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
55. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
56. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
57. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience.
Fitriakusumah Y; Lesmana CRA; Bastian WP; Jasirwan COM; Hasan I; Simadibrata M; Kurniawan J; Sulaiman AS; Gani RA
BMC Gastroenterol; 2019 Mar; 19(1):43. PubMed ID: 30894137
[TBL] [Abstract][Full Text] [Related]
58. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
59. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
[TBL] [Abstract][Full Text] [Related]
60. Nonalcoholic fatty liver disease in children: recent practice guidelines, where do they take us?
Aggarwal A; Puri K; Thangada S; Zein N; Alkhouri N
Curr Pediatr Rev; 2014; 10(2):151-61. PubMed ID: 25088269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]